Design and synthesis of a β-lactamase activated 5-fluorouracil prodrug

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 4, 2009, Pages 1261-1263

  Phelan, Ryan M ^a   Ostermeier, Marc ^b   Townsend, Craig A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Johns Hopkins University   (United States)

Author keywords

5 Fluorouracil; Beta lactam; Cephalosporin; Cephalosporin derivatization

Indexed keywords

BETA LACTAMASE; CEPHALOSPORIN; FLUOROURACIL; FLUOROURACIL CEPHALOSPORIN PRODRUG; PRODRUG; UNCLASSIFIED DRUG;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ARTICLE; DRUG ACTIVATION; DRUG CONJUGATION; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; ENTEROBACTER CLOACAE; GENE DIRECTED ENZYME PRODRUG THERAPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ANTINEOPLASTIC AGENTS; BETA-LACTAMASES; CEPHALOSPORINS; DRUG SCREENING ASSAYS, ANTITUMOR; ENTEROBACTER CLOACAE; FLUOROURACIL; PRODRUGS;

ENTEROBACTER CLOACAE;

EID: 59649099693     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.12.057     Document Type: Article

References (26)

1. Greco O., and Dachs G.U. J. Cell. Physiol. 187 (2001) 22
2. Jung M. Mini Rev. Med. Chem. 1 (2001) 399
3. Kerr D.E., Li Z.G., Siemers N.O., Senter P.D., and Vrudhula V.M. Bioconjugate Chem. 9 (1998) 255
4. Vrudhula V.M., Svensson H.P., and Senter P.D. J. Med. Chem. 40 (1997) 2788
5. Rodrigues M.L., Carter P., Wirth C., Mullins S., Lee A., and Blackburn B.K. Chem. Biol. 2 (1995) 223
6. Zlokarnik G., Negulescu P.A., Knapp T.E., Mere L., Burres N., Feng L., Whitney M., Roemer K., and Tsien R.Y. Science 279 (1998) 84
7. Li Q., Lee J.Y., Castillo R., Hixon M.S., Pujol C., Doppalapudi V.R., Shepard H.M., Wahl G.M., Lobl T.J., and Chan M.F. Antimicrob. Agents Chemother. 46 (2002) 1262
8. Gao W., Xing B., Tsien R.Y., and Rao J. J. Am. Chem. Soc. 125 (2003) 11146
9. Tang X., Cai T., and Wang P.G. Bioorg. Med. Chem. Lett. 13 (2003) 1687
10. Vrudhula V.M., Svensson H.P., Kennedy K.A., Senter P.D., and Wallace P.M. Bioconjugate Chem. 4 (1993) 334
11. Alexander R.P., Beeley N.R.A., Odriscoll M., Oneill F.P., Millican T.A., Pratt A.J., and Willenbrock F.W. Tetrahedron Lett. 32 (1991) 3269
12. Svensson H.P., Frank I.S., Berry K.K., and Senter P.D. J. Med. Chem. 41 (1998) 1507
13. Svensson H.P., Kadow J.F., Vrudhula V.M., Wallace P.M., and Senter P.D. Bioconjugate Chem. 3 (1992) 176
14. Vrudhula V.M., Svensson H.P., and Senter P.D. J. Med. Chem. 38 (1995) 1380
15. Jungheim L.N., Shepherd T.A., and Kling J.K. Heterocycles 35 (1993) 339
16. Hanessian S., and Wang J.G. Can. J. Chem. 71 (1993) 896
17. Jungheim L.N., Shepherd T.A., and Meyer D.L. J. Org. Chem. 57 (1992) 2334
18. Rothenberg M., Navarro M., Butts C., Bang Y., Cox J., Goel R., Gollins S., Siu L., and Cunningham D. Ann. Oncol. 18 (2007) 17
19. 2: 493.1. Found: 493.1.
20. 4: 231. Found: 231.
21. Jacobsen M.F., Knudsen M.M., and Gothelf K.V. J. Org. Chem. 71 (2006) 9183
22. Kaiser G.V., Cooper R.D.G., Koehler R.E., Murphy C.F., Webber J.A., Wright I.G., and Vanheyni E. J. Org. Chem. 35 (1970) 2430
23. Lee M., Hesek D., and Mobashery S. J. Org. Chem. 70 (2005) 367
24. 2: 687.1. Found: 687.1.
25. 2: 467. Found: 467.
26. The βL cleavage assay was preformed on an Agilent (Santa Clara, CA) 1100 HPLC using a Phenomenex (Torrance, CA) Luna C-18 reverse phase column. All compounds were run using an isocratic mobile phase consisting of 30% acetonitrile in 0.1% trifluoroacetic acid. All compounds were monitored at 267 nm.